/news

Midday Report: Neogenomics (NEO) Shares Up on June 22

Equities Staff  |

Neogenomics Inc. (NASDAQ: NEO) has climbed $0.415 (5.54%) and sits at $7.86, as of 12:05:03 est on June 22.

663,698 shares have exchanged hands.

The Company has increased 4.61% over the last 5 days and shares lost 14.79% over the last 30 days.

Neogenomics anticipates its next earnings on 2022-08-04.

For technical charts, analysis, and more on Neogenomics visit the company profile.

About Neogenomics Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

To get more information on Neogenomics Inc. and to follow the company's latest updates, you can visit the company's profile page here: Neogenomics Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Will Mining Stocks Fall Further?
3 Reasons To Be Optimistic About the Global Shipping Industry
The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks



Market Movers

Sponsored Financial Content